Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From SciSparc Ltd.
Indoco has seen double-digit growth in domestic and international markets in the first quarter of financial year 2022. Headquartered in Mumbai, Indoco has reported overall growth of almost 43% and an increase of 124.6% in its operating profit in Q1 FY22.
The generics industry struggled with the prior-year comparison as it saw an expected decline in revenues in the first quarter of 2021, driven by the global impact of the COVID-19 crisis. As a result, the performance of most companies fell short of the numbers reported in Q1 2020. However, a few managed to contradict the trend by reporting growth, either based on the launch of COVID-related drugs or performance in specific geographies.
In tandem with buying the rest of Kleo, Tonix licenses molecular degradation technology from Yale. Neurogene, University of Dundee partner on cell therapies for neurological disorders.
India’s Indoco has reported double-digit growth despite a slow recovery of its domestic business during its financial third quarter ended 31 December 2020. The Indian company reported 18% sales growth overall, lifted by 73% growth in its International business in Q3.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- NasVax Ltd.
- Therapix Biosciences Ltd.